SAB Biotherapeutics (SABS) Current Deferred Revenue: 2020-2024
Historic Current Deferred Revenue for SAB Biotherapeutics (SABS) over the last 2 years, with Sep 2024 value amounting to $114,698.
- SAB Biotherapeutics' Current Deferred Revenue fell 92.95% to $114,698 in Q3 2024 from the same period last year, while for Sep 2024 it was $114,698, marking a year-over-year decrease of 92.95%. This contributed to the annual value of $1.3 million for FY2023, which is N/A change from last year.
- Latest data reveals that SAB Biotherapeutics reported Current Deferred Revenue of $114,698 as of Q3 2024, which was down 0.00% from $114,698 recorded in Q2 2024.
- In the past 5 years, SAB Biotherapeutics' Current Deferred Revenue registered a high of $2.9 million during Q1 2023, and its lowest value of $100,000 during Q4 2020.
- Over the past 2 years, SAB Biotherapeutics' median Current Deferred Revenue value was $1.3 million (recorded in 2023), while the average stood at $1.3 million.
- Data for SAB Biotherapeutics' Current Deferred Revenue shows a maximum YoY crashed of 96.04% (in 2024) over the last 5 years.
- SAB Biotherapeutics' Current Deferred Revenue (Quarterly) stood at $100,000 in 2020, then remained steady at $100,000 in 2021, then reached $1.3 million in 2023, then crashed by 92.95% to $114,698 in 2024.
- Its last three reported values are $114,698 in Q3 2024, $114,698 for Q2 2024, and $377,835 during Q1 2024.